Human endothelial cell migration is stimulated by urokinase plasminogen activator: Plasminogen activator inhibitor I complex released from endometrial stromal cells stimulated with transforming growth factor β1; possible mechanism for paracrine stimulation of endometrial angiogenesis

Biology of Reproduction

Volumn 59, Issue 4, 1998, Pages 759-767

  Sandberg, Tove ^a   Casslén, Bertil ^a   Gustavsson, Barbro ^a   Benraad, Theo J ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Catholic Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE;

ANGIOGENESIS; ARTICLE; CELL ADHESION; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; ENDOMETRIUM; ENDOTHELIUM; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; UMBILICAL VEIN;

CELL LINE; CELL MOVEMENT; CULTURE TECHNIQUES; ENDOMETRIUM; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IODINE RADIOISOTOPES; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; PARACRINE COMMUNICATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREGNANCY; RNA, MESSENGER; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA; UMBILICAL VEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0031688261     PISSN: 00063363     EISSN: None     Source Type: Journal    
DOI: 10.1095/biolreprod59.4.759     Document Type: Article

References (54)

1. Ferenczy A, Bertrand G, Gelfand MM. Proliferation kinetics of human endometrium during the normal menstrual cycle. Am J Obstet Gynecol 1979; 133:859-867.
2. Goodger A, Rogers P. Endometrial endothelial cell proliferation during the menstrual cycle. Hum Reprod 1994; 9:399-405.
3. Rogers P, Abberton K, Susil B. Endothelial cell migratory signal produced by human endometrium during the menstrual cycle. Hum Reprod 1992; 7:1061-1066.
4. Yamamoto T, Terada N, Nishizawa Y, Petrow V. Angiostatic activities of medroxyprogesterone acetate and its analogues. Int J Cancer 1994; 56:393-399.
5. Peek M, Markham R, Fraser I. The effects of natural and synthetic sex steroids on human decidual endothelial cell proliferation. Hum Reprod 1995; 10:2238-2243.
6. Massagué J. The transforming growth factor-b family. Annn Rev Cell Biol 1990; 6:597-641.
7. Roberts AB, Sporn MB. The transforming growth factor-βs. In: Peptide Growth Factors and Their Receptors I. Berlin: Springer Verlag; 1990: 419-472.
8. Chegini N, Zhao Y, Williams RS. Flanders KC. Human uterine tissue throughout the menstrual cycle expresses transforming growth factor-beta 1 (TGF beta 1), TGF beta 2, TGF beta 3, and TGF beta type II receptor messenger ribonucleic acid and protein and contains [I-125]TGF beta 1-binding sites. Endocrinology 1994; 135:439-449.
9. Gold LI, Saxena B, Mittal KR. Increased expression of transforming growth factor beta isoforms and basic fibroblast growth factor in complex hyperplasia and adenocarcinoma of the endometrium - evidence for paracrine and autocrine action. Cancer Res 1994; 54:2347-2358.
10. Marshburn PB, Arici AM, Casey ML. Expression of transforming growth factor-beta 1 messenger ribonucleic acid and the modulation of deoxyribonucleic acid synthesis by transforming growth factor-beta 1 in human endometrial cells. Am J Obstet Gynecol 1994; 170:1152-1158.
11. Casslén B, Sandberg T, Gustavsson B, Willén R, Nilbert M. Transforming growth factor β1 in the endometrium. Cyclic variation, increased expression by estradiol and progesterone, and regulation of plasminogen activators and plasminogen activator inhibitor-1. Biol Reprod 1998; 58:1343-1350
12. Odekon LE, Blasi F, Rifkin DB. Requirement for receptor-bound urokinase in plasmin-dependent cellular conversion of latent TGF-β to TGFβ. J Cell Physiol 1994; 158:398-407.
13. Casslén B, Nordengren J, Gustavsson B, Nilbert M, Lund LR. Progesterone stimulates degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells by increasing its inhibitor (PAI1) and surface expression of the u-PA receptor. J Clin Endocrinol Metab 1995; 80:2776-2784.
14. Rybo G. Plasminogen activators in the endometrium. Acta Obstet Gynecol Scand 1966; 45:97-118.
15. Casslén B, & Aring§edt B. Fibrinolytic activity of human uterine fluid. Acta Obstet Gynecol Scand 1981; 60:55-58.
16. Casslén B, Thorell J, & Aring§edt B. Effect of IUD on urokinase-like immunoreactivity and plasminogen activators in human uterine fluid. Contraception 1981; 23:435-446.
17. Roberts AB, Sporn MB, Assoian RK. Transforming growth factor type b: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1986; 83:4167-4171.
18. Yang EY, Moses HL. Transforming growth factor b-1 induced changes in cell migration, proliferation and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 1990; 111:731-741.
19. Phillips GD, Whitehead RA, Stone AM, Ruebel MW, Goodkin ML, Knighton DR. Transforming growth factor-beta (TGF-B) stimulation of angiogenesis - an electron microscopic study. J Submicrosc Cytol Pathol 1993; 25:149-155.
20. Baird ATD. Inhibition of endothelial cell proliferation by type-b transforming growth factor: interactions with acidic and basic fibroblasts growth factor. Biochem Biophys Res Commun 1986; 138:476-182.
21. Frater-Schroder M, Muller G, Birchmeier W, Bohlen P. TGFβ inhibits endothelial cell proliferation. Biochem Biophys Res Commun 1986; 137:295-302.
22. Casslén B, Siler-Khodr T, Harper M. Progesterone regulation of prolactin release from human endometrial stromal cells in culture: potential bio-assay for progestational activity. Acta Endocrinol 1990; 122: 137-144.
23. Jaffe EA. Culture and identification of large vessel endothelial cells. In: Jaffe EA (ed.). Biology of Endothelial Cells. Boston: Martinus Nijhoff Publishers; 1984: 1-13.
24. Xu Y, Swerlick RA, Sepp N, Bosse D, Ades EW, Lawley TJ. Characterization of expression and modulation of cell adhesion molecules on an immortalized human dermal microvascular endothelial cell line (HMEC-1). J Invest Dermatol 1994; 102:833-837.
25. Casslén B, Urano S, Lecander I, Ny T. Plasminogen activators in the human endometrium, cellular origin and hormonal regulation. Blood Coagul Fibrinolysis 1992; 3:133-138.
26. Grebenschikov N, Geurts-Moespot A, De White H. A sensitive and robust assay for urokinase and tissue-type plasminogen activators (uPA and tPA) and their inhibitor type 1 (PAI1) in breast tumor cytosols. Int J Biol Markers 1997; 12:6-4.
27. 125I to high specific activity. Biochim Biophys Acta 1971; 251:363-369.
28. Thomas PS. Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose. Proc Natl Acad Sci USA 1980: 77:5201-5205.
29. Feinberg AP, Vogelstein B. A technique for radiolabelling DNA restriction fragments to high specific activity. Anal Biochem 1984; 137: 266-267.
30. Ny T, Sawdey M, Lawrence D, Millan J, Loskutoff D. Cloning and sequence of a cDNA coding for the human b-migrating endothelial-cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83:6776-6780.
31. Verde P, Stoppelli MP, Galeffi P, Dinocera PP, Blasi F. Identification and primary sequence of an unspliced human urokinase poly(A)+ RNA. Proc Natl Acad Sci USA 1984; 81:4727-4731.
32. Roldan AL, Cubellis MV, Masucci MT. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 1990; 9:467-474.
33. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J Cell Biol 1988; 107:1199-1205.
34. Sandberg T, Eriksson P, Gustavsson B, Casslén B. Differential regulation of the plasminogen activator inhibitor-1 (PAI1) gene expression by growth factors and progesterone in endometrial stromal cells. Mol Human Reprod 1997; 3:781-787.
35. Dumler I, Petri T, Schleuning WD. Interaction of urokinase-type plasminogen activator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein. FEBS Lett 1993; 322:37-40.
36. Dumler I, Petri T, Schleuning WD. Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett 1994; 343:103-106.
37. Rabbani SA, Desjardins J, Bell AW. An amino-terminal fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173: 1058-1064.
38. Nusrat AR, Chapman HA Jr. An autocrine role for urokinase in phorbol ester-mediated differentiation of myeloid cell lines. J Clin Invest 1991; 87:1091-1097.
39. Waltz DA, Sailor LZ, Chapman HA. Cytokines induce urokinase-dependent adhesion of human myeloid cells. A regulatory role for plasminogen activator inhibitors. J Clin Invest 1993; 91:1541-1552.
40. Odekon LE, Sato Y, Rifkin DB. Urokinase-type plasminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 1992; 150:258-263.
41. Gyetko MR, Todd RF, Wilkinson CC, Sitrin RG. The urokinase receptor is required for human monocyte chemotaxis in vitro. J Clin Invest 1994; 93:1380-1387.
42. Cubellis M, Andreasen P, Ragno P, Mayer M, Danø K. Blasi F. Accessibility of receptor-bound urokinase to type-1 plasminogen activator inhibitor. Proc Natl Acad Sci USA 1989; 86:4828-4832.
43. Casslén B, Gustavsson B, Nordengren J, Angelin B, Gåfvels M. Degradation of urokinase plasminogen activator (u-PA) in endometrial stromal cells requires both the u-PA receptor and the LDL receptor-related protein (LRP)/alpha-2 macroglobulin receptor. Mol Human Reprod 1998; 4:585-593.
44. Heinmark RL, Twardzik DR, Schwartz SM. Inhibition of endothelial regeneration by type beta transforming growth factor from platelets. Science 1986; 233:1078-1080.
45. Muller G, Behrens J, Nussbaumer U, Bohlen P, Birchmeier W. Inhibitory action of transforming growth factor β on endothelial cells. Proc Natl Acad Sci USA 1987; 84:5600-5604.
46. Wahl SM, Hunt DA, Wakefield LM. Transforming growth factor b induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84:5788-5795.
47. Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988; 157:793-800.
48. Leibovich SJ, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-a. Nature 1988; 329:630-632.
49. Peek MJ, Markham R, Fraser IS. Angiogenic activity in normal and dysfunctional uterine bleeding human endometrium; as measured by the chick chorioallantoic membrane assay. Exp Toxicol Pathol 1995; 47:397-402.
50. Rogers PAW, Au CL, Affandi B. Endometrial microvascular density during the normal menstrual cycle and following exposure to long-term levonorgestrel. Hum Reprod 1993; 8:1396-1404.
51. Lawrence DA, Berkenpas MB, Palaniappan S. Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269:15223-15228.
52. Stephens RW, Bokman AM, MyšhŠnen HT. Heparin binding to the urokinase kringle domain. Biochemistry 1992; 31:7572-7579.
53. Stephens RW, Aumailley M, Timpl R. Urokinase binding to lamininnidogen. Structural requirements and interactions with heparin. Eur J Biochem 1992; 207:937-942.
54. Sutton AB, Canfield AE, Schor SL, Grant ME, Schor AM. The response of endothelial cells to TGFβ-1 is dependent upon cell shape, proliferative state and the nature of the substratum. J Cell Sci 1991; 99:777-787.